Product description
- Transino is one of the best Japanese skin whitening brands. The product received the biggest award in Japan for its new effectiveness in treating melasma.
- Transino’s cosmetic products receive widespread public approval and support for the effective and beneficial effects it brings to users.
- Transino II is the only OTC drug approved in Japan as being effective against skin blemishes caused by Melasma.
Features and Benefits
- Treats all types of melasma, including hormonal melasma, preventing melasma, freckles from returning.
- Remove age spots caused by sunlight.
- Evenly whiten skin tone from face to body, anti-aging, improve physiological ability and symptoms of frigidity.
- Support the treatment of skin inflammation, body eczema.
- Balances estrogen, enhances female physiology.
- Leaves skin white, smooth, and youthful.
How to use
- Take the following amount with water or hot water.
- Adults (15 years old and over):
- Take 2 tablets at a time twice daily after meals.
- Do not use for children under 15 years old.
Precautions
- Please strictly observe the usage and dosage.
- Store in a cool, dry place out of direct sunlight.
- Please keep out of reach of children.
Ingredients
- Tranexamic Acid: is one of the ingredients that help treat melasma, freckles safely have a blurring effect. brown spots, improve dark skin, whiten skin quickly.
- Vitamin C: antioxidant, evens skin tone, fades scars, helps skin to be healthy from deep within. In addition, the active ingredient also has the ability to reduce sebum secretion and tighten pores.
- L – Cysteine: helps slow down the aging process, has the ability to increase elasticity and regenerate skin after acne.
- Vitamin B6: is responsible for maintaining moisture, regulating sebum for the skin, helping to treat acne and inflammation effectively. It is a substance that plays an important role in skin regeneration.
- Vitamin B5: keeps your skin hydrated, soothes skin, prevents redness and acne. Is an excellent antioxidant.
Reviews
There are no reviews yet.